Abstract
The ability of cancer cells to migrate is strongly correlated with malignant progression and metastasis. Survival signals that suppress apoptosis have also been linked to increased cell motility. We previously reported that suppression of protein kinase Cδ (PKCδ) provided survival signals in a rat fibroblast model system. These studies have been extended to human breast cancer cells with differential cell motilities and PKCδ levels. BT-549 cells, which lack detectable expression of PKCδ, migrate very efficiently, whereas MCF-7 cells, which express high levels of PKCδ, migrate very poorly. Ectopic expression of PKCδ suppressed cell migration in the BT-549 cells, and downregulation of PKCδ enhanced cell migration in the MCF-7 cells. Downregulation of PKCδ in the MCF-7 cells also led to increased secretion of the matrix metalloprotease MMP-9. The migration of mouse embryo fibroblasts (MEFs) from wild type and PKCδ knockout mice was also examined and MEFs from PKCδ knockout mice had a five-fold increase in cell migration relative to the wild-type MEFs. These data provide evidence that PKCδ suppresses cell migration in both human breast cancer cells and in primary mouse fibroblasts, and indicate that the loss of PKCδ in human cancers could contribute to both cell survival and metastasis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abbas T, White D, Hui L, Foster DA and Bargonetti J . (2004). J. Biol. Chem., 279, 9970–9977.
Acs P, Wang QJ, Bogi K, Marquez AM, Lorenzo PS, Biro T, Szallasi Z, Mushinski JF and Blumberg PM . (1997). J. Biol. Chem., 272, 28793–28799.
Aguirre-Ghiso JA, Frankel P, Farias EF, Lu Z, Jiang H, Olsen A, Feig LA, de Kier Joffe EB and Foster DA . (1999). Oncogene, 18, 4718–4725.
Bartucci M, Morelli C, Mauro L, Ando S and Surmacz E . (2002). Cancer Res., 61, 6747–6754.
Biscardi JS, Tice DA and Parsons SJ . (1999). Adv. Cancer Res., 76, 61–119.
Clamp A and Jayson GC . (2002). Anticancer Drugs, 13, 673–683.
Di Cristofano A and Pandolfi PP . (2000). Cell, 100, 387–390.
Hata A, Akita Y, Suzuki K and Ohno S . (1993). J. Biol. Chem., 268, 9122–9129.
Hennings H, Blumberg PM, Pettit GR, Herald CL, Shores R and Yuspa SH . (1987). Carcinogenesis, 8, 1343–1346.
Hornia A, Lu Z, Sukezane T, Zhong M and Foster DA . (1999). Mol. Cell. Biol., 19, 7672–7680.
Huppi K, Siwarski D, Goodnight J and Mischak H . (1994). Genomics, 19, 161–162.
Jackson D and Foster DA . (2004). FASEB J., 18, 627–636.
Johnson MD, Torri JA, Lippman ME and Dickson RB . (1999). Exp. Cell Res., 247, 105–113.
Kiley SC, Clark KJ, Duddy SK, Welch DR and Jaken S . (1999a). Oncogene, 18, 6748–6757.
Kiley SC, Clark KJ, Goodnough M, Welch DR and Jaken S . (1999b). Cancer Res., 59, 3230–3238.
Kruger JS and Reddy KB . (2003). Mol. Cancer Res,, 1, 801–809.
Liu JF, Crepin M, Liu JM, Barritault D and Ledoux D . (2002). Biochem. Biophys. Res. Commun., 293, 1174–1182.
Lu Z, Hornia A, Jiang YW, Frankel P, Zang Q and Foster DA . (1997). Mol. Cell. Biol., 17, 3418–3428.
Lu Z, Liu D, Hornia A, Devonish W, Pagano M and Foster DA . (1998). Mol. Cell. Biol., 18, 839–845.
Marshall JL, Bangalore N, El-Ashry D, Fuxman Y, Johnson M, Norris B, Oberst M, Ness E, Wojtowicz-Praga S, Bhargava P, Rizvi N, Baidas S and Hawkins MJ . (2002). Cancer Biol. Ther., 1, 409–416.
Mischak H, Goodnight JA, Kolch W, Martiny-Baron G, Schaechtle C, Kazanietz MG, Blumberg PM, Pierce JH and Mushinski JF . (1993). J. Biol. Chem., 268, 6090–6096.
Miyamoto A, Nakayama K, Imaki H, Hirose S, Jiang Y, Abe M, Tsukiyama T, Nagahama H, Ohno S, Hatakeyama S and Nakayama KI . (2002). Nature, 416, 865–869.
Nieves-Neira W and Pommier Y . (1999). Int. J. Cancer, 82, 396–404.
Ohno S, Mizuno K, Adachi Y, Hata A, Akita Y, Akimoto K, Osada S, Hirai S and Suzuki K . (1994). J. Biol. Chem., 269, 17495–17501.
Reddig PJ, Dreckschmidt NE, Ahrens H, Simsiman R, Tseng CP, Zou J, Oberley TD and Verma AK . (1999). Cancer Res., 59, 5710–5718.
Sevignani C, Calin GA, Cesari R, Sarti M, Ishii H, Yendamuri S, Vecchione A, Trapasso F and Croce CM . (2003). Cancer Res., 63, 1183–1187.
Sliva D, Rizzo MT and English D . (2002). J. Biol. Chem., 277, 3150–3157.
Stetler-Stevenson WG and Yu AE . (2001). Semin. Cancer Biol., 11, 143–152.
Sugatani T, Alvarez U and Hruska KA . (2003). J. Biol. Chem., 278, 5001–5008.
Szallasi Z, Denning MF, Smith CB, Dlugosz AA, Yuspa SH, Pettit GR and Blumberg PM . (1994a). Mol. Pharmacol., 46, 840–850.
Szallasi Z, Smith CB, Pettit G and Blumberg PM . (1994b). J. Biol. Chem., 269, 2118–2124.
Yang Q, Yoshimura G, Mori I, Sakurai T and Kakudo K . (2000). J. Hum. Genet., 47, 453–459.
Yoshida K, Miki Y and Kufe D . (2002). J. Biol. Chem., 277, 48372–48378.
Zabarovsky ER, Lerman MI and Minna JD . (2002). Oncogene, 21, 6915–6935.
Zhong M, Lu Z, Abbas T, Hornia A, Chatakondu K, Barile N, Kaplan P and Foster DA . (2001). Cell Growth Differ., 12, 187–192.
Zhong M, Lu Z and Foster DA . (2002). Oncogene, 21, 1071–1078.
Acknowledgements
We thank Shigeo Ohno (Yokohama) for generously providing the PKCδ expression vector used in this study. This study was supported by National Institutes of Health grants RO1-CA46677 and SO6-GM60654. DJ was supported by a minority supplement to CA46677. Research Centers in Minority Institutions award RR-03037 from the National Center for Research Resources of the National Institutes of Health, which supports infrastructure and instrumentation in the Biological Sciences Department at Hunter College, is also acknowledged.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jackson, D., Zheng, Y., Lyo, D. et al. Suppression of cell migration by protein kinase Cδ. Oncogene 24, 3067–3072 (2005). https://doi.org/10.1038/sj.onc.1208465
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208465
Keywords
This article is cited by
-
Superbinder based phosphoproteomic landscape revealed PRKCD_pY313 mediates the activation of Src and p38 MAPK to promote TNBC progression
Cell Communication and Signaling (2024)
-
Discovery of a small-molecule protein kinase Cδ-selective activator with promising application in colon cancer therapy
Cell Death & Disease (2018)
-
Co-dependency of PKCδ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer
Oncogene (2017)
-
Protein kinase Cδ is required for ErbB2-driven mammary gland tumorigenesis and negatively correlates with prognosis in human breast cancer
Oncogene (2014)
-
Protein kinase C and cancer: what we know and what we do not
Oncogene (2014)